World Therapy: Pouchitis – Pipeline Review, H1 2012

• Publication date: March 2012

This report provides data on the therapeutic development for Pouchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pouchitis . 'Pouchitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentation...

This report provides data on the therapeutic development for Pouchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pouchitis . 'Pouchitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Pouchitis .
- A review of the Pouchitis products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pouchitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Pouchitis .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pouchitis pipeline depth and focus of Pouchitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents

Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global March kets Direct Report Coverage 4
Pouchitis Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Pouchitis 6
Pouchitis Therapeutics under Development by Firms 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Pouchitis Therapeutics – Products under Development by Firms 10
Companies Involved in Pouchitis Therapeutics Development 11
Ocera Therapeutics, Inc. 11
Atlantic Pharmaceuticals, Inc. 12
AesRx, LLC. 13
Pouchitis – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
Alicaforsen - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AST-120 - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Aes-210 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Pouchitis Therapeutics – Drug Profile Updates 24
Pouchitis Therapeutics - Dormant Products 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

List of Tables
Number of Products Under Development for Pouchitis, H1 2012 6
Products under Development for Pouchitis – Comparative Analysis, H1 2012 7
Number of Products under Development by Firms, H1 2012 8
Comparative Analysis by Mid Clinical Stage Development, H1 2012 9
Products under Development by Firms, H1 2012 10
Ocera Therapeutics, Inc., H1 2012 11
Atlantic Pharmaceuticals, Inc., H1 2012 12
AesRx, LLC., H1 2012 13
Assessment by Monotherapy Products, H1 2012 14
Assessment by Stage and Route of Administration, H1 2012 16
Assessment by Stage and Molecule Type, H1 2012 18
Pouchitis Therapeutics – Drug Profile Updates 24
Pouchitis Therapeutics – Dormant Products 25

List of Figures

List of Figures
Number of Products under Development for Pouchitis, H1 2012 6
Products under Development for Pouchitis – Comparative Analysis, H1 2012 7
Products under Development by Firms, H1 2012 8
Mid Clinical Stage Products, H1 2012 9
Assessment by Monotherapy Products, H1 2012 14
Assessment by Route of Administration, H1 2012 15
Assessment by Stage and Route of Administration, H1 2012 16
Assessment by Molecule Type, H1 2012 17
Assessment by Stage and Molecule Type, H1 2012 18